Home › Neuroblastoma › California
Neuroblastoma clinical trials in California
14 studies for Neuroblastoma are looking for participants at sites in California.
Cities in California
- Los Angeles7 studies
- San Francisco7 studies
- Mountain View5 studies
- Oakland5 studies
- San Diego5 studies
- Orange3 studies
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- and 13 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 2, 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- University of California, San Francisco, San Francisco
Recruiting
All ages · All sexes · Updated Oct 1, 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Children's Hospital Los Angeles, Los Angeles
- and 9 more
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital of Orange County, Orange
- UCSF Medical Center-Mission Bay, San Francisco
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
RecruitingPhase 2
12 Months – 21 Years · All sexes · Updated Aug 12, 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
- Stanford University, Palo Alto
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
- University of California, San Francisco, San Francisco
RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Jul 22, 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital Los Angeles, Los Angeles
- UCSF Benioff Children's Hospital, San Francisco
RecruitingPhase 2
Ages 1 to 31 · All sexes · Updated Jul 20, 2026 · NCT06450041Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Lucille Packard Children's Hospital Stanford, Palo Alto
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 2 to 30 · All sexes · Updated May 7, 2026 · NCT06500819Neuroblastoma Biology Study
- Children's Hospital Los Angeles, Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RecruitingObservational study
31 Days – 99 Years · All sexes · Updated Mar 23, 2026 · NCT01587300From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.